Abstract:Abstract Development of new drugs is of high interest for the field of cardiac and cardiovascular diseases, which are a dominant cause of death worldwide. Before being allowed to be used and distributed, every new potentially therapeutic compound must be strictly validated during preclinical and clinical trials. The preclinical studies usually involve the in vitro and in vivo evaluation. Due to the increasing reporting of discrepancy in drug effects in animal and humans and the requirement to reduce the number of animals used in research, improvement of in vitro models based on human cells is indispensable. Primary cardiac cells are difficult to access and maintain in cell culture for extensive experiments; therefore, the human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) became an excellent alternative. This technology enables a production of high number of patient- and disease-specific cardiomyocytes and other cardiac cell types for a large-scale research. The drug effects can be extensively evaluated in the context of electrophysiological responses with a use of well-established tools, such as multielectrode array (MEA), patch clamp, or calcium ion oscillation measurements. Cardiotoxicity, which is a common reason for withdrawing drugs from marketing or rejection at final stages of clinical trials, can be easily verified with a use of hiPSC-CM model providing a prediction of human-specific responses and higher safety of clinical trials involving patient cohort. Abovementioned studies can be performed using two-dimensional cell culture providing a high-throughput and relatively lower costs. On the other hand, more complex structures, such as engineered heart tissue, organoids, or spheroids, frequently applied as co-culture systems, represent more physiological conditions and higher maturation rate of hiPSC-derived cells. Furthermore, heart-on-a-chip technology has recently become an increasingly popular tool, as it implements controllable culture conditions, application of various stimulations and continuous parameters read-out. This paper is an overview of possible use of cardiomyocytes and other cardiac cell types derived from hiPSC as in vitro models of heart in drug research area prepared on the basis of latest scientific reports and providing thorough discussion regarding their advantages and limitations.

Heart-on-a-chip systems with tissue-specific functionalities for physiological, pathological, and pharmacological studies

Engineering Cardiac Tissue for Advanced Heart‐on‐a‐chip Platforms

Fabrication and Biomedical Applications of Heart-on-a-chip

Biomimetic Cardiac Microsystems for Pathophysiological Studies and Drug Screens

Recent developments in organ-on-a-chip technology for cardiovascular disease research

Design and fabrication of an integrated heart-on-a-chip platform for construction of cardiac tissue from human iPSC-derived cardiomyocytes and in situ evaluation of physiological function

Organ-on-a-chip technology: a novel approach to investigate cardiovascular diseases

Sensor-free and Sensor-based Heart-on-a-chip Platform: A Review of Design and Applications

Recent progress of organ-on-a-chip towards cardiovascular diseases: advanced design, fabrication, and applications

Architecture design and advanced manufacturing of heart-on-a-chip: scaffolds, stimulation and sensors

Organ-on-a-Chip: New Platform for Biological Analysis.

Micro‐Engineered Heart Tissues on‐Chip with Heterotypic Cell Composition Display Self‐Organization and Improved Cardiac Function

Organs-On-Chips and Its Applications

A heart-on-a-chip platform for online monitoring of contractile behavior via digital image processing and piezoelectric sensing technique

Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function

Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems.

Advances in Human Organs-on-Chips and Applications for Drug Screening and Personalized Medicine

Engineered human cardiac tissues for modeling heart diseases

Developing organs-on-chips for biomedical applications

Heart‐on‐a‐Chip Model of Epicardial–Myocardial Interaction in Ischemia Reperfusion Injury (Adv. Healthcare Mater. 21/2024)

Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research